Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADHERE+ Open-label Extension Study of Efgartigimod in CIDP
NCT04280718Phase 2Active, not recruiting
- Sponsor
- argenx
- Start
- Sep 2020
- Primary completion
- Apr 2027
- Modality
- Antibody Fragments
- Countries
- 24
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Sep 2020; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT04280718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280718.